Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
Year: 2019
Type: article
Abstract: Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed/refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CAR T cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas.
Authors: Tania Jain, Merav Bar, Ankit J. Kansagra, Elise A. Chong, Shahrukh K. Hashmi, Sattva S. Neelapu, Michael Byrne, Elad Jacoby, Aleksandr Lazaryan, Caron A. Jacobson, Stephen M. Ansell, Farrukh T. Awan, Linda Burns, Veronika Bachanova, Catherine M. Bollard, Paul A. Carpenter, John F. DiPersio, Mehdi Hamadani, Helen E. Heslop, Joshua A. Hill, Krishna V. Komanduri, Craig A. Kovitz, Hillard M. Lazarus, Justin M. Serrette, Mohamad Mohty, David Miklos, Arnon Nagler, Steven Z. Pavletic, Bipin N. Savani, Stephen J. Schuster, Mohamed A. Kharfan-Dabaja, Miguel-Angel Perales, Yi Lin
Institutions: Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, University of Washington, Fred Hutch Cancer Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Abramson Cancer Center, University of Pennsylvania, Mayo Clinic, King Faisal Specialist Hospital & Research Centre, The University of Texas MD Anderson Cancer Center, Vanderbilt University, Vanderbilt University Medical Center, Tel Aviv University, Sheba Medical Center, Moffitt Cancer Center, Dana-Farber Cancer Institute, National Marrow Donor Program, University of Minnesota, Children's National, Washington University in St. Louis, Medical College of Wisconsin, Baylor College of Medicine, Sylvester Comprehensive Cancer Center, Case Western Reserve University, The University of Texas Medical Branch at Galveston, Inserm, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Stanford University, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), Cornell University, Weill Cornell Medicine
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
Awards: G1411362006, SPORE in Lymphoma
OpenAlex ID: W2969216121